期刊
JOURNAL OF NUCLEAR MEDICINE
卷 59, 期 3, 页码 469-478出版社
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.117.198119
关键词
PROMISE; miTNM; PSMA-ligand PET/CT; standardized evaluation; interpretation; criteria
资金
- Deutsche Forschungsgemeinschaft [807122, Sonderforschungsbereich 824]
- Fondation ARC pour la recherche sur le cancer [SAE20160604150]
Prostate-specific membrane antigen (PSMA)-ligand PET imaging provides unprecedented accuracy for whole-body staging of prostate cancer. As PSMA-ligand PET/CT is increasingly adopted in clinical trials and routine practice worldwide, a unified language for image reporting is urgently needed. We propose a molecular imaging TNM system (miTNM, version 1.0) as a standardized reporting framework for PSMA-ligand PET/CT or PET/MRI. miTNM is designed to organize findings in comprehensible categories to promote the exchange of information among physicians and institutions. Additionally, flowcharts integrating findings of PSMA-ligand PET and morphologic imaging have been designed to guide image interpretation. Specific applications, such as assessment of prognosis or impact on management, should be evaluated in future trials. miTNM is a living framework that evolves with clinical experience and scientific data.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据